#Isosorbide Sales Market share
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
Tumblr was the first site to host the blog for President Barack Obama in 2011.
Text
Isosorbide Sales Market Analysis, Manufacturing, Analysis and Forecasts 2018-2025|Hexa Reports
In this report, the Global Isosorbide Market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.
Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Isosorbide for these regions, from 2013 to 2025 (forecast), covering
United States
China
Europe
Japan
Southeast Asia
India
Request A Sample copy of This Report @ http://www.hexareports.com/report/global-isosorbide-sales-market-report-2018/request-sample
Global Isosorbide market competition by top manufacturers/players, with Isosorbide sales volume, Price (USD/MT), revenue (Million USD) and market share for each manufacturer/player; the top players including
Roquette
SK Chemicals
Ecogreen Oleochemicals
ADM
Novaphene
Yu Teng
Hongbaifeng
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split int
Industrial Grade
Pharmaceutical Grade
Browse Detail Report With TOC @ http://www.hexareports.com/report/global-isosorbide-sales-market-report-2018
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
Plastics and Polymers
Cosmetic
Pharmaceutical
Other
If you have any special requirements, please let us know and we will offer you the report as you want.
Table Of Content
Global Isosorbide Sales Market Report 2018
Global Isosorbide Competition by Players/Suppliers, Type and Application
United States Isosorbide (Volume, Value and Sales Price)
China Isosorbide (Volume, Value and Sales Price)
Europe Isosorbide (Volume, Value and Sales Price)
Japan Isosorbide (Volume, Value and Sales Price)
Southeast Asia Isosorbide (Volume, Value and Sales Price)
India Isosorbide (Volume, Value and Sales Price)
Global Isosorbide Players/Suppliers Profiles and Sales Data
Isosorbide Maufacturing Cost Analysis
For More Details Visits @ Hexa Reports
0 notes
Text
Commodity Plastics Market Strategic Insights and key Business Influencing Factors | Major Players – Formosa Plastics Corporation, Gas Authority of India Limited(GAIL), Hanwha Co. Ltd.
Commodity Plastics Market is the types of plastics that are used in a wide variety of applications and have day to day usage. Most of the commodity plastics has billions of applications, including packaging, electronics, automobiles and healthcare. Most commonly commodity plastics resins are transformed into sheets & films for further use. Some plastics such as polyethylene terephthalate (PET) are directly molded in bottles and other forms.
Global commodity plastic market is expected to register a healthy CAGR of 4.3% in the forecast period of 2018 to 2025.
Get Sample Report at :
https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-commodity-plastics-market
Competitive Analysis: Global Commodity Plastics Market
Some of the prominent participants operating in this market are Exxon Mobil, Sinopec Corporation, Chevron Phillips Chemical Company, Basf SE, DowDuPont, Lyondellbasell Industries Holdings B.V., Borealis AG, Braskem, Eni S.P.A, Formosa Plastics Corporation, Gas Authority of India Limited(GAIL), Hanwha Co. Ltd, Indian Oil Corporation, Ineos, LG Chem, Ltd., Lotte Chemical, Mitsubishi Chemical Corporation, Nova Chemicals Corporation, PTT Global Chemical Public Company Limited, Qatar Petroleum, Qenos Pty Ltd, Reliance Industries Limited, Sabic, Sumitomo Chemical Company Limited, Westlake Chemical Corporation among others.
Key Pointers Covered in the Global Commodity Plastics Market Trends and Forecast to 2026
Global Commodity Plastics Market New Sales Volumes
Global Commodity Plastics Market Replacement Sales Volumes
Global Commodity Plastics Market Installed Base
Global Commodity Plastics Market By Brands
Global Commodity Plastics Market Size
Global Commodity Plastics Market Procedure Volumes
Global Commodity Plastics Market Product Price Analysis
Global Commodity Plastics Market Healthcare Outcomes
Global Commodity Plastics Market Cost of Care Analysis
Global Commodity Plastics Market Regulatory Framework and Changes
Global Commodity Plastics Market Prices and Reimbursement Analysis
Global Commodity Plastics Market Shares in Different Regions
Recent Developments for Global Commodity Plastics Market Competitors
Global Commodity Plastics Market Upcoming Applications
Global Commodity Plastics Market Innovators Study
Get Detailed TOC:
https://www.databridgemarketresearch.com/toc/?dbmr=global-commodity-plastics-market
Recent Developments:
In October 2018, Braskem announced the supply of green plastics for Rio de Janeiro brand Cafe Favorito. This green plastics is considered as first polyethylene obtained from renewable origin. The renewable resin is produced from sugarcane and is 100% recyclable resin, which will be used for the manufacturing of coffee pillow packs of 500g capacity.
In October 2018, the company announced to expand its product portfolio for polyethylene (PE) and polypropylene (PP), under the brand name Borealis Bormed PL8830-PH for the healthcare industry portfolio.
In December2017, mitsubishi chemical corporation had developed bio-based engineering plastics under the brand name DURABIO, for large automotive exterior components. This newly developed DURABIO is made from isosorbide, deriving from renewable plants.
Scope of the Commodity Plastics Market
Global Commodity Plastics Market, By Product type (Polyethylene, Polyvinyl Chloride, Polystyrene, Polypropylene, polymethyl methacrylate), Application (Packaging, automotive, electronics, consumer goods, construction, textile, medical & pharmaceutical and others), Geography (North America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025
A Commodity Plastic is the types of plastics that are used in a wide variety of applications and have day to day usage. Most of the commodity plastics has billions of applications, including packaging, electronics, automobiles and healthcare. Most commonly commodity plastics resins are transformed into sheets & films for further use. Some plastics such as polyethylene terephthalate (PET) are directly molded in bottles and other forms.
Global commodity plastic market is expected to register a healthy CAGR of 4.3% in the forecast period of 2018 to 2025.
Speak to Author :
https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-commodity-plastics-market
Key insights in the report:
Complete and distinct analysis of the market drivers and restraints
Key Market players involved in this industry
Detailed analysis of the Market Segmentation
Competitive analysis of the key players involved
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
Browse Related Report Here:
Slip Additives Market
Syngas - Derivatives Market
#Commodity Plastics Market#Commodity Plastics Market share#Commodity Plastics Market size#Commodity Plastics Market trends#Commodity Plastics Market news#Commodity Plastics Market report
0 notes
Text
Angina Pectoris Treatment Market Poised to Expand at a Robust Pace Over
Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heart’s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest. The factors that trigger stable angina pectoris include, emotional stress, exposure to very hot or cold temperature, heavy meals or smoking. Angina pectoris can be diagnosed by an electrocardiogram and angiography and could be treated by medication, change in life style, and surgery. A minimal invasive procedure known as angioplasty is also used to treat the angina pectoris. The pain or discomfort caused by angina pectoris is relieved with rest and nitroglycerin. Nitroglycerin relaxes the coronary arteries and other blood vessels by increasing the blood flow to the heart vessels.
Request A Sample Copy: http://bit.ly/32FHrqo
New product launches and strong pipeline is expected to fuel the growth of angina pectoris treatment market
Espero announced in June 2016, that the company received approval from the U.S. Food and Drug Administration (FDA) for GoNitro (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris, due to coronary artery disease. In February 2016, AstraZeneca sold the rights of its two medicines Plendil and Imdur for US $500Mn. China Medical System Holdings (CMS) agreed to pay AstraZeneca US $310 million for commercialization rights of Plendil (felodipine) in China. Plendil is a calcium antagonist indicated for both hypertension and the prophylaxis of the chronic stable angina pectoris. Whereas, Imdur is an oral extended-release formulation of isosorbide mononitrate indicated for the prevention of angina pectoris, due to coronary artery disease.
Furthermore, Amgen offers a product named Corlanor (Ivabradine) for the treatment of angina pectoris in its pipeline (phase 3), which was presented by the company in year 2015 at Annual Scientific Session. In November 2016, Allergan also presented new data on BYSTOLIC (nebivolol) for the treatment of hypertension to lower blood pressure at the Annual American Heart Association Meeting in New Orleans. Whereas, Perrigo announced FDA approval of its abbreviated new drug application (ANDA) for Nitroglycerin Lingual Spray in 2013, the generic version of Shionogi's Nitrolingual Pumpspray indicated for acute attacks and prophylaxis of angina pectoris.
Strategic activities by market players to increase their market share
Angina pectoris treatment market is driven by factors, such as increasing number of collaborations, product launches, and mergers and acquisition. For instance, Recordati acquired AstraZeneca blood pressure brand Metoprolol, in 2017, which is a beta-blocker used mainly for the conditions, such as angina pectoris, hypertension, and heart disorders. Furthermore, Pharmaceutical manufacturer Lupin received approval from U.S. FDA in 2017 to launch the generic version of the U.S WorldMeds’ nadolol drug indicated for the patients with angina pectoris and for the treatment of hypertension. Moreover, patent expiry of Ranolazine drug from Gilead Sciences, Inc. in 2019 would mark the opportunity for generic drug manufacturers in the global angina pectoris treatment market.
The key players operating in the global market of angina pectoris treatment market include Abbott Laboratories, Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Allergan plc, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and Sanofi SA.
Click To Read More On: Angina Pectoris Treatment Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Angina Pectoris Treatment Market 2019 with Top 20 Countries data : Trends and Growth Factors
Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heart’s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest. The factors that trigger stable angina pectoris include, emotional stress, exposure to very hot or cold temperature, heavy meals or smoking. Angina pectoris can be diagnosed by an electrocardiogram and angiography and could be treated by medication, change in life style, and surgery. A minimal invasive procedure known as angioplasty is also used to treat the angina pectoris. The pain or discomfort caused by angina pectoris is relieved with rest and nitroglycerin. Nitroglycerin relaxes the coronary arteries and other blood vessels by increasing the blood flow to the heart vessels.
Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1158
New product launches and strong pipeline is expected to fuel the growth of angina pectoris treatment market
Espero announced in June 2016, that the company received approval from the U.S. Food and Drug Administration (FDA) for GoNitro (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris, due to coronary artery disease. In February 2016, AstraZeneca sold the rights of its two medicines Plendil and Imdur for US $500Mn. China Medical System Holdings (CMS) agreed to pay AstraZeneca US $310 million for commercialization rights of Plendil (felodipine) in China. Plendil is a calcium antagonist indicated for both hypertension and the prophylaxis of the chronic stable angina pectoris. Whereas, Imdur is an oral extended-release formulation of isosorbide mononitrate indicated for the prevention of angina pectoris, due to coronary artery disease.
Furthermore, Amgen offers a product named Corlanor (Ivabradine) for the treatment of angina pectoris in its pipeline (phase 3), which was presented by the company in year 2015 at Annual Scientific Session. In November 2016, Allergan also presented new data on BYSTOLIC (nebivolol) for the treatment of hypertension to lower blood pressure at the Annual American Heart Association Meeting in New Orleans. Whereas, Perrigo announced FDA approval of its abbreviated new drug application (ANDA) for Nitroglycerin Lingual Spray in 2013, the generic version of Shionogi’s Nitrolingual Pumpspray indicated for acute attacks and prophylaxis of angina pectoris.
Strategic activities by market players to increase their market share
Angina pectoris treatment market is driven by factors, such as increasing number of collaborations, product launches, and mergers and acquisition. For instance, Recordati acquired AstraZeneca blood pressure brand Metoprolol, in 2017, which is a beta-blocker used mainly for the conditions, such as angina pectoris, hypertension, and heart disorders. Furthermore, Pharmaceutical manufacturer Lupin received approval from U.S. FDA in 2017 to launch the generic version of the U.S WorldMeds’ nadolol drug indicated for the patients with angina pectoris and for the treatment of hypertension. Moreover, patent expiry of Ranolazine drug from Gilead Sciences, Inc. in 2019 would mark the opportunity for generic drug manufacturers in the global angina pectoris treatment market.
The key players operating in the global market of angina pectoris treatment market include Abbott Laboratories, Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Allergan plc, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and Sanofi SA.
Click To Reading More On Angina Pectoris Treatment Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected]
0 notes
Text
Sorbitol Market Emerging Trends and Strong Application Scope by 2018
A recent study by Transparency Market Research (TMR) forecasts that the global sorbitol market will grow at a healthy CAGR of 3.4% from 2012 to 2018. TMR, a leading market intelligence firm based in the U.S., says in its latest report that the demand for sorbitol was 1,699.7 kilo tons in 2011, and will surge to 2,148.9 kilo tons by the end of 2018. The report is titled ‘Global Sorbitol Market - Isosorbide, Propylene Glycol, Glycerol & Other Downstream Opportunities, Applications Size, Share, Growth, Trends And Forecast 2012 - 2018’
The growing awareness regarding health concerns, particularly in the context of using healthier alternatives to sugar, is a key driver boosting the sorbitol market. Sorbitol is a basic raw material required in the production of surfactants and Vitamin C. As compared to other dietary sugars, sorbitol is a metabolized slowly.
The use of sorbitol is increasing in the global market because it is being explored as a base chemical for production of propylene glycols, ethylene glycols, and glycerols – all predominantly derived from petrochemicals. The product base in the sorbitol market is almost the same as other polyols and isosorbides. Such an increasing application scope for isosorbides and polyols has resulted in a high potential for sorbitol market.
The study also analyzes various sorbitol product forms that include crystal and liquid. Liquid sorbitol is mainly manufactured based on numerous processes such as purification of dextrose, hydrogenation, and purification. Crystal sorbitol, on the other hand, is obtained after spray-drying, incurring extra cost. Liquid sorbitol accounted for 83.3% of the overall demand in 2011 and continues to dominate the global sorbitol product segments.
Similarly, toothpaste, diabetic and dietetic F and B, Vitamin C, and surfactants are some of the key applications within the global sorbitol market. Diabetic and dietetic F and B and toothpaste accounted for 23.6% and 21.3% of the overall demand in 2011, respectively.
Request to view Sample Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=847
As sorbitol is less sweet in comparison to other sugar alcohols, this market finds growing applications in various industry verticals including pharmaceutical, food & beverage, cosmetic and personal care, and the chemical industry. It is the relatively low sweetness in sorbitol that makes it a preferential choice among several diabetic patients across the globe. The rising diabetic and dietetic population is primarily boosting the market growth of sorbitol. Sorbitol allows the diabetic population to enjoy the sweetness of sugar and control their weight and other dietary illnesses. Hence, increasing sorbitol application as a low-calorie sweetener is expected to boost the global demand for sorbitol over the next five years.
Excessive sweetness creates dental problems and that is precisely why sorbitol is preferred to sugar, as it inhibits the formation of acids in the mouth that results in dental cavities. However, the global sorbitol market is restrained by variable raw material prices and side effects caused by sorbitol upon excessive consumption.
In terms of consumption, North America and Europe dominated the global sorbitol market in the earlier stages. The European sorbitol market is expected to grow at a rapid CAGR of 12.5% from 2012 to 2018. Demand for sorbitol soars in Asia-Pacific as well. The Asia Pacific sorbitol demand is mainly dominated by four regions including India, Indonesia, China, and Japan.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States
Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email:[email protected] Website: http://www.transparencymarketresearch.com
0 notes
Text
Anti-anginal Drugs Market Size,Status and Forecast 2025
Anti-anginal drugs are also known as anti-anginal agents. The management of angina is done through a variety of anti-anginal drugs. Angina is a heart condition in which the arteries of the heart, known as coronary arteries, become narrow. The primary symptom associated with angina is severe chest pain. Anti-anginal agents include nitrates, calcium antagonists, beta blockers, and Ranolazine. Examples of nitrates include nitroglycerin, isosorbide mono-nitrate, and isosorbide di-nitrate. These drugs help by relaxing the smooth muscle inside the blood vessels, making it wide and helping in the easy transfer of oxygen and blood to the heart. Examples of the calcium antagonists include verapamil, nimodipine, nifedipine, and diltiazem. These antagonists inhibit the contraction of the vascular smooth muscles due to their ability to inhibit calcium transfer into the cells. Examples of beta blockers include metoprolol, pindolol, propranolol, and atenolol. These drugs help in slowing down the heartbeat.
Read Report Overview: https://www.transparencymarketresearch.com/anti-anginal-drugs-market.html
The exact way in which Ranolazine exerts its anti-anginal effect is not yet known. It is assumed that during cardiac repolarization, Ranolazine inhibits the ion channels. Anti-anginal drugs help in the treatment of Raynaud’s syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attack, esophageal spasm, cyanide poisoning, angina pectoris prophylaxis, angina, and anal fissure and fistula. Raynaud’s syndrome is an indication of blockage of blood flow to the nose, ears, toes, and fingers, causing blood vessel spasms due to experiencing of strong emotions or cold temperatures. Pulmonary hypertension occurs due to narrowing of the small arteries of the lung, making it difficult for the blood to flow, thereby increasing the blood pressure. Under this condition, the right side of the heart pumps blood harder. Hence, the size of the heart increases over a period of time, resulting in heart failure. Heart failure is a condition in which the heart is not able to transfer nutrients and oxygen to the rest of the body. Heart attack is a condition of permanent damage or death of an area of the heart muscle due to inadequate supply of oxygen to that part of the heart.
Esophageal spasms occur when the food in the esophagus does not effectively propel down to the stomach due to irregular contractions of muscles in the esophagus. The measures undertaken to prevent discomfort due to coronary heart disease or chest pain is known as angina pectoris prophylaxis. Rise in prevalence of Raynaud’s syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attack, esophageal spasms, cyanide poisoning, angina pectoris prophylaxis, angina, and anal fissure and fistula is projected to drive the anti-anginal drugs market during the forecast period. According to the Raynaud’s Association, 15 million to 30 million people in the U.S. are affected with Raynaud’s syndrome.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42011
The global anti-anginal drugs market can be segmented on the basis of mode of action, indication, dosage form, distribution channel, and region. Based on mode of action, the anti-anginal drugs market can be categorized into nitrates, calcium antagonists, beta blockers, and Ranolazine. In terms of indication, the anti-anginal drugs market can be classified into Raynaud’s syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attack, esophageal spasms, cyanide poisoning, angina pectoris prophylaxis, angina, and anal fissure and fistula. Based on dosage form, the anti-anginal drugs market can be divided into ointments and tablets. In terms of distribution channel, the anti-anginal drugs market can be bifurcated into retail pharmacies, online pharmacies, and hospital pharmacies.
Geographically, the global anti-anginal drugs market can be segmented into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America accounted for the dominant share of the anti-anginal drugs market in 2016 due to increase in prevalence of the heart failure and heart attack in the region. Europe constituted the next leading share of the anti-anginal drugs market share in 2016 owing to increase in prevalence of high blood pressure in the region. The anti-anginal drugs market in Asia Pacific is anticipated to expand at a significant rate during the forecast period. The anti-anginal drugs market in Middle East & Africa and Latin America is projected to expand during the forecast period owing to increase in initiatives undertaken by the governments to prevent incidences of heart attack and heart failure in these regions.
Request For TOC : https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=42011
Key players operating in the global anti-anginal drugs market include Pfizer Inc., MEDA Manufacturing GmbH, Valeant Pharmaceuticals International, Inc., and Gilead Sciences.
About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact us:
Transparency Market Research 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 USA – Canada Toll Free 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com/
0 notes
Text
Isosorbide Market 2018 to Earn a Valuation of USD 605.71 billion by 2022
Isosorbide industry -Regional Outlook and Trend Analysis In 2015, Asia Pacific region emerged as the top customer as reporting for around 34% of the overall volume. It is also anticipated to be the top-growing region during the forecast period. The rising bioplastics demand primarily in China is likely to act as a major driving factor for product demand during the approaching years. Key biotechnology and chemical companies like Roquette Freres have been transferring their production bases to low-cost nations like India, China, Indonesia, and Thailand. In 2015, the demand for Product in Europe was esteemed around USD 77 million. The rising demand for bio-based plastics in the emerging countries of Europe is likely to act positively over the forthcoming years. Encouraging regulatory scenario, boosting sustainable alchemy is projected to be the major market driving factors over the coming years. North American region emerged as the 3rd top customer and is anticipated to grow at a compound annual growth rate of 11.1% during the next few years. Growing demand for bio-based product together with technological advancements in the region is likely to act as a key driving factor for industry growth during the next few years.
Request sample Copy of this Report: www.crystalmarketresearch.com/report-sample/CM09234 Isosorbide industry -Competitive Insights: Major market players for the global isosorbide market are; Par Pharmaceutical, Jinan Hongbaifeng Industry And Trade Co., Ltd., Ecogreen Oleochemicals, Roquette Freres, Novaphene, JP Laboratories, Mitsubishi corporation, SK Chemicals Co., Ltd., and Cargill. Isosorbide is presently a very niche market and is commanded by France’s Roquette Freres. Other global players such as Novaphene, and SK Chemicals Co., Ltd. are also anticipated to commercialize their produces in the coming years. Though, the existence of huge unorganized industry primarily in China presents a great risk to these international companies. Isosorbide -Industry Outlook and Trend Analysis: The Isosorbide Market was evaluated around USD 271.32 million in 2014 and is anticipated to reach approximately USD 605.71 billion by the end of 2022 with a compound annual growth rate (CAGR) of 9.18% during the forecast period, owing to the growing demand for substituting fossil fuel by-products in applications like polymers, monomers, functional materials, and solvents. Isosorbide by-products such as dinitrate and mononitrate find its uses primarily in medical and pharmaceutical which is expected to augment the growth of the global market during the forecast years. Growth factors affecting on Isosorbide Market: The demand of the product is mainly fueled by currently expanding the capacity of the bio-plastic industry. Due to rising demand of bio-based PET in Asia Pacific and Europe, PEIT is likely to direct the application section during the approaching years. Asia Pacific region holds the major share, on account of growing construction and manufacturing activities from India, China, as well as few other Southeast Asian nations. Bio-based plastics production capacities in China region have experienced improved usage rate during the precedent years. This can be assigned to low labor cost and raw material. Constant study on isosorbide usage in functional polymers has turn out to be productive and ensued as a few companies embracing its application methods as an additive or monomer. Rising ecological concern about the utilization of synthetic polymers has encouraged the EPA to enforce strict regulations, which consecutively has recommended the top polymer and biotechnological companies to expand innovative technology using recyclable raw materials. Browse Full market data Tables and in-depth TOC on Isosorbide Market: www.crystalmarketresearch.com/report/isosorbide-market The Isosorbide Market is segmented as follows- Isosorbide Market, By Application, Estimates and Forecast, 2014-2022 ($Million) Polyethylene Isosorbide Terephthalate (PEIT) Polycarbonate Polyurethane Polyester Polyisosorbide Succinate Isosorbide Diesters Other Application Isosorbide Market, By End-Use Type, Estimates and Forecast, 2014-2022 ($Million) Resins & Polymers Additives Other End-Use Type End User Outlook and Trend Analysis: Polymers and Resins are projected to be the highest-growing sector, with numerous application chances on the prospect. In 2015, polymers and Resins segment reported for around 47% of the overall revenue. The change in trend for bio-based products in plastics and polymers sector is anticipated to fuel the product demand during the coming years. Key chemical companies like SK Chemicals and Mitsubishi Chemicals have been concentrating on the fabrication of bio-based polymers for electrical, electronics, and automotive. Additives are a rising opportunity for isosorbide and are projected to experience the highest growth with a considerable compound annual growth rate during the forecast period. Increasing importance for recyclable polymer additives in fuel additives and fuels is likely to fuel the growth of the segment across the long term. Reasons to buy a Exclusive report? 1) An extensive research study on the Global Isosorbide market, and its entire ecosystem, describes the market trends, drivers, restraints and opportunities of the Isosorbide market. 2) We provide you the longest possible market segmentation based on type of products, procedures and geography and describe the market share region wise. 3) The report gives a bird eyes view on the competitive landscape which includes mergers and acquisitions, collaborations, market strategies, and new product launches. Click to Buy In-depth TOC "Exclusive report": www.crystalmarketresearch.com/checkout/CM09234 Major TOC of Isosorbide Market: Chapter1. Introduction Chapter2. Executive Summary Chapter3. Market Overview Chapter 4.Isosorbide Market, By Application 4.1.Introduction 4.2.Isosorbide Market Assessment and Forecast, By Application, 2014-2022 4.3.Polyethylene Isosorbide Terephthalate (PEIT) 4.3.1.1.Market Assessment and Forecast, By Region, 2014-2022 ($Million) 4.4.Polycarbonate 4.4.1.1.Market Assessment and Forecast, By Region, 2014-2022 ($Million) 4.5.Polyurethane 4.5.1.1.Market Assessment and Forecast, By Region, 2014-2022 ($Million) 4.6.Polyester Polyisosorbide Succinate 4.6.1.1.Market Assessment and Forecast, By Region, 2014-2022 ($Million) 4.7.Isosorbide Diesters 4.7.1.1.Market Assessment and Forecast, By Region, 2014-2022 ($Million) 4.8.Other Applications 4.8.1.1.Market Assessment and Forecast, By Region, 2014-2022 ($Million) Chapter 5.Isosorbide Market, By End-Use Type 5.1.Introduction 5.2.Isosorbide Market Assessment and Forecast, By End-Use Type, 2014-2022 ($Million) 5.3.Resins & Polymers 5.3.1.1.Market Assessment and Forecast, By Region, 2014-2022 ($Million) 5.4.Additives 5.4.1.1.Market Assessment and Forecast, By Region, 2014-2022 ($Million) 5.5.Other End-Use Types 5.5.1.1.Market Assessment and Forecast, By Region, 2014-2022 ($Million) Chapter6. Isosorbide Market, By Region Chapter7. Company Profiles Chapter8. Global Isosorbide Market Competition, by Manufacturer Chapter9. Isosorbide Market Forecast (2018-2022) …CONTINUED FOR TOC To get Discounts and customized details here: www.crystalmarketresearch.com/check-discount/CM09234 About Crystal Market Research: Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customized research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy. Contacts Us Judy | 304 South Jones Blvd, Suite 1896, Las Vegas NV 89107, United States E-mail: [email protected] | Ph: +1-888-213-4282 Web: www.crystalmarketresearch.com
0 notes
Text
Anti-anginal Drugs Market to Surge at a Robust Pace by 2025
Anti-anginal drugs are also known as anti-anginal agents. The management of angina is done through a variety of anti-anginal drugs. Angina is a heart condition in which the arteries of the heart, known as coronary arteries, become narrow. The primary symptom associated with angina is severe chest pain. Anti-anginal agents include nitrates, calcium antagonists, beta blockers, and Ranolazine. Examples of nitrates include nitroglycerin, isosorbide mono-nitrate, and isosorbide di-nitrate. These drugs help by relaxing the smooth muscle inside the blood vessels, making it wide and helping in the easy transfer of oxygen and blood to the heart. Examples of the calcium antagonists include verapamil, nimodipine, nifedipine, and diltiazem. These antagonists inhibit the contraction of the vascular smooth muscles due to their ability to inhibit calcium transfer into the cells. Examples of beta blockers include metoprolol, pindolol, propranolol, and atenolol. These drugs help in slowing down the heartbeat.
The exact way in which Ranolazine exerts its anti-anginal effect is not yet known. It is assumed that during cardiac repolarization, Ranolazine inhibits the ion channels. Anti-anginal drugs help in the treatment of Raynaud's syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attack, esophageal spasm, cyanide poisoning, angina pectoris prophylaxis, angina, and anal fissure and fistula. Raynaud's syndrome is an indication of blockage of blood flow to the nose, ears, toes, and fingers, causing blood vessel spasms due to experiencing of strong emotions or cold temperatures. Pulmonary hypertension occurs due to narrowing of the small arteries of the lung, making it difficult for the blood to flow, thereby increasing the blood pressure. Under this condition, the right side of the heart pumps blood harder. Hence, the size of the heart increases over a period of time, resulting in heart failure. Heart failure is a condition in which the heart is not able to transfer nutrients and oxygen to the rest of the body.
Heart attack is a condition of permanent damage or death of an area of the heart muscle due to inadequate supply of oxygen to that part of the heart. Esophageal spasms occur when the food in the esophagus does not effectively propel down to the stomach due to irregular contractions of muscles in the esophagus. The measures undertaken to prevent discomfort due to coronary heart disease or chest pain is known as angina pectoris prophylaxis. Rise in prevalence of Raynaud's syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attack, esophageal spasms, cyanide poisoning, angina pectoris prophylaxis, angina, and anal fissure and fistula is projected to drive the Anti-Anginal Drugs Market during the forecast period. According to the Raynaud’s Association, 15 million to 30 million people in the U.S. are affected with Raynaud's syndrome.
Request to View Brochure of Report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42011
The global anti-anginal drugs market can be segmented on the basis of mode of action, indication, dosage form, distribution channel, and region. Based on mode of action, the anti-anginal drugs market can be categorized into nitrates, calcium antagonists, beta blockers, and Ranolazine. In terms of indication, the anti-anginal drugs market can be classified into Raynaud's syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attack, esophageal spasms, cyanide poisoning, angina pectoris prophylaxis, angina, and anal fissure and fistula. Based on dosage form, the anti-anginal drugs market can be divided into ointments and tablets. In terms of distribution channel, the anti-anginal drugs market can be bifurcated into retail pharmacies, online pharmacies, and hospital pharmacies.
Geographically, the global anti-anginal drugs market can be segmented into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America accounted for the dominant share of the anti-anginal drugs market in 2016 due to increase in prevalence of the heart failure and heart attack in the region. Europe constituted the next leading share of the anti-anginal drugs market share in 2016 owing to increase in prevalence of high blood pressure in the region. The anti-anginal drugs market in Asia Pacific is anticipated to expand at a significant rate during the forecast period. The anti-anginal drugs market in Middle East & Africa and Latin America is projected to expand during the forecast period owing to increase in initiatives undertaken by the governments to prevent incidences of heart attack and heart failure in these regions.
Key players operating in the global anti-anginal drugs market include Pfizer Inc., MEDA Manufacturing GmbH, Valeant Pharmaceuticals International, Inc., and Gilead Sciences.
Enquiry for discount on this report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=42011
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com
0 notes
Text
Global Transdermal Drug Patches Sales Market Report 2018 - 24 Market Reports
[2018 Updated Market Report] Global Transdermal Drug Patches Sales Market Report 2018
Sahil Sharma's insight:
This report studies the global Transdermal Drug Patches market status and forecast, categorizes the global Transdermal Drug Patches market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).
A transdermal drug patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Transdermal patches are presently being marketed which can be worn anywhere from as little as eight hours to as long as seven days, depending on their therapeutic indication.
Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/global-transdermal-drug-patches2018-672
Transdermal drug patches production has relatively high technology barrier and is technology intensive industry. Currently, there are many producing companies in the USA transdermal drug patches industry. The main market players are Noven, Mylan, Novartis and Johnson & Johnson. The production of transdermal drug patches will increase to 477482 K Units in 2016 from 340530 K Units in 2011 with average growth rate of 7.00%. USA transdermal drug patches capacity utilization rate remained at around 76.86% in 2015.
Transdermal drug patches mainly has some types, which include fentanyl transdermal patch, nicotine transdermal patch, buprenorphine transdermal patch, clonidine transdermal patch and oxybutynin transdermal patch. With medical effect of transdermal drug patches, the downstream application industries will need more transdermal drug patches products.
The major raw materials for transdermal drug patches are scopolamine, clonidine, nitroglycerin, isosorbide dinitrate, estradiol, norethindrone acetate and fentanyl, etc. Fluctuations in the price of the upstream product will impact on the production cost of transdermal drug patches, and then impact the price of transdermal drug patches. The production cost of transdermal drug patches is also an important factor which could impact the price of transdermal drug patches. The transdermal drug patches manufacturers are trying to produce many more types of transdermal drug patches for other different diseases.
The global Transdermal Drug Patches market is valued at xx million US$ in 2017 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2018-2025.
The major players covered in this report
Noven
Mylan
Novartis
Johnson & Johnson
Agile Therapeutics
Teikoku Pharma USA
Immune Pharmaceuticals
Hercon Pharmaceuticals
Pocono
DURECT Corporation
Xel Pharmaceuticals
Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
United States
Europe
China
Japan
Southeast Asia
India
We can also provide the customized separate regional or country-level reports, for the following regions:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Rest of Asia-Pacific
Europe
Germany
France
UK
Italy
Spain
Russia
Rest of Europe
Central & South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Saudi Arabia
Turkey
Rest of Middle East & Africa
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Fentanyl Transdermal Patch
Nicotine Transdermal Patch
Buprenorphine Transdermal Patch
Clonidine Transdermal Patch
Oxybutynin Transdermal Patch
Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
Used for Hypertension
Used for Contraception
Used for Analgesia
Used for Smoking Cessation
Used for Angina
Used for Hormone Replacement
The study objectives of this report are:
To analyze and study the global Transdermal Drug Patches sales, value, status (2013-2017) and forecast (2018-2025);
To analyze the top players in North America, Europe, China, Japan, Southeast Asia and India, to study the sales, value and market share of top players in these regions.
Focuses on the key Transdermal Drug Patches players, to study the sales, value, market share and development plans in future.
Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
To define, describe and forecast the market by type, application and region.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Transdermal Drug Patches are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders
Transdermal Drug Patches Manufacturers
Transdermal Drug Patches Distributors/Traders/Wholesalers
Transdermal Drug Patches Subcomponent Manufacturers
Industry Association
Downstream Vendors
Available Customizations
With the given market data, we offers customizations according to the company’s specific needs. The following customization options are available for the report:
Regional and country-level analysis of the Transdermal Drug Patches market, by end-use.
Detailed analysis and profiles of additional market players.
Get the Complete Report & TOC @ https://www.24marketreports.com/life-sciences/global-transdermal-drug-patches2018-672
Table of content Global Transdermal Drug Patches Sales Market Report 2018 1 Transdermal Drug Patches Market Overview 1.1 Product Overview and Scope of Transdermal Drug Patches 1.2 Classification of Transdermal Drug Patches by Product Category 1.2.1 Global Transdermal Drug Patches Market Size (Sales) Comparison by Type (2013-2025) 1.2.2 Global Transdermal Drug Patches Market Size (Sales) Market Share by Type (Product Category) in 2017 1.2.3 Fentanyl Transdermal Patch 1.2.4 Nicotine Transdermal Patch 1.2.5 Buprenorphine Transdermal Patch 1.2.6 Clonidine Transdermal Patch 1.2.7 Oxybutynin Transdermal Patch 1.2.8 Others 1.3 Global Transdermal Drug Patches Market by Application/End Users 1.3.1 Global Transdermal Drug Patches Sales (Volume) and Market Share Comparison by Application (2013-2025) 1.3.1 Used for Hypertension 1.3.2 Used for Contraception 1.3.3 Used for Analgesia 1.3.4 Used for Smoking Cessation 1.3.5 Used for Angina 1.3.6 Used for Hormone Replacement 1.4 Global Transdermal Drug Patches Market by Region 1.4.1 Global Transdermal Drug Patches Market Size (Value) Comparison by Region (2013-2025) 1.4.2 United States Transdermal Drug Patches Status and Prospect (2013-2025) 1.4.3 Europe Transdermal Drug Patches Status and Prospect (2013-2025)
If You Have Any Question Related To This Report Contact Us @ https://www.24marketreports.com/enquire-now/global-transdermal-drug-patches2018-672
CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 Fax: (+1) 212 634 4885 Email: [email protected]
Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports
0 notes
Text
Sorbitol Market Forecasting Include Market drivers and restrains, along with their current and expected impact 2012-2020
Global Sorbitol Market is expected to reach USD 3.99 billion by 2020, according to a new study by Grand View Research, Inc. Sorbitol is a preferred substitute for sugar in food and beverages owing to lower caloric values and natural sweetening properties. Additionally, increasing health awareness among consumers worldwide is expected to fuel market demand over the forecast period.
Cosmetic and personal care was the largest end use application segment, accounting for over 600 kilo tons of sorbitol demand in 2013. Stabilizing, softening and surface active properties of sorbitol are the key reasons for growing use in the above applications. Sorbitol is also used as a preservative and low calorie sweetener in foods and accounted for over 537.9 kilo tons of sorbitol demand in 2013.
Access Full Research Report on Global Sorbitol Market: http://www.grandviewresearch.com/industry-analysis/sorbitol-market
Further key findings from the study suggest:
Global sorbitol demand was 1,829.6 kilo tons in 2013 and is expected to reach 2,337.2 kilo tons by 2020 growing at a CAGR of 3.6% from 2014 to 2020.
Liquid sorbitol is the largest used product, accounting for 1,524.7 kilo tons of demand in 2013, mainly due to simplified production process and low cost in comparison to crystal sorbitol.
Toothpaste is the fastest growing application segment, at an estimated CAGR of 4.0% from 2014 to 2020 mainly due to sorbitol properties that prevent cavities and tooth decay.
Asia Pacific was the largest regional market for sorbitol with revenue USD 656.9 million in 2013. China being the largest producer of Vitamin C, a key application of sorbitol, has resulted in highest demand in the region. In addition, the region is also expected to witness fastest growth, at an estimated CAGR of 4.1% from 2014 to 2020.
Cosmetic and personal care along with chemical applications are expected to witness fastest growth at an estimated CAGR of 3.8% from 2014 to 2020.
Key Companies in the market include Roquette Freres, Cargill and Archer Daniels Midland which together accounted for a market share of over 70% in 2013. Other companies include Sorini, Gulshan Polylols Ltd, SPI Pharma, Merck, Danisco and Sigma-Aldrich.
View More related reports from same category: http://www.grandviewresearch.com/industry/food-additives-nutricosmetics-flavors-and-fragrances
For the purpose of this study, Grand View Research has segmented the Global Sorbitol Market on the basis of product, application, end use application and region:
• Sorbitol Product Outlook (Volume, Kilo Tons; Revenue, USD Million, 2012 - 2020)
• Liquid/Syrup sorbitol
• Crystal/Powder sorbitol
• Sorbitol Applications Outlook (Volume, Kilo Tons; Revenue, USD Million, 2012 - 2020)
• Toothpaste
• Vitamin C
• Diabetic and Dietetic Food and Beverage
• Surfactants
• Others
• Sorbitol End Use Applications Outlook (Volume, Kilo Tons; Revenue, USD Million, 2012 - 2020)
• Cosmetic and Personal Care
• Chemical
• Food
• Pharmaceutical
• Others
• Sorbitol Downstream Opportunities Outlook
• Ethylene Glycol
• Propylene Glycol
• Glycerol
• Isosorbide
• Sorbitol Regional Outlook (Volume, Kilo Tons; Revenue, USD Million, 2012 - 2020)
• North America
• Europe
• Asia Pacific
• RoW
View Press Release on Global Sorbitol Market By Grand View Research: http://www.grandviewresearch.com/press-release/global-sorbitol-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
For more Information visit us: www.grandviewresearch.com
0 notes
Text
Isosorbide Industry Key Manufacturers, Analysis and 2022 Forecasts for Global and Chinese Markets
ReportsWeb has announced the addition of the “Isosorbide Industry Global and Chinese Market Research Report 2017” report to their offering. This report provides Isosorbide industry analysis for the international markets including development trends, growth, competitive analysis and key manufacturer development status.
The 'Global and Chinese Isosorbide Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Isosorbide industry with a focus on the Chinese market.
The report provides key statistics on the market status of the Isosorbide manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail.
Complete report is available at http://www.reportsweb.com/isosorbide-industry-global-and-chinese-market-research-report-2017
In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Isosorbide industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2017-2022 market development trends of Isosorbide industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.
In the end, the report makes some important proposals for a new project of Isosorbide Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2012-2022 global and Chinese Isosorbide industry covering all important parameters.
Get sample copy at http://www.reportsweb.com/inquiry&RW0001599485/sample
Few Points from Table of Contents
Chapter One Introduction of Isosorbide Industry Chapter Two Manufacturing Technology of Isosorbide Chapter Three Analysis of Global Key Manufacturers Chapter Four 2012-2017 Global and Chinese Market of Isosorbide Chapter Five Market Status of Isosorbide Industry Chapter Six 2017-2022 Market Forecast of Global and Chinese Isosorbide Industry
Chapter Seven Analysis of Isosorbide Industry Chain Chapter Eight Global and Chinese Economic Impact on Isosorbide Industry Chapter Nine Market Dynamics of Isosorbide Industry Chapter Ten Proposals for New Project Chapter Eleven Research Conclusions of Global and Chinese Isosorbide Industry
Discount copy is available at http://www.reportsweb.com/inquiry&RW0001599485/discount
Few Points from List of Tables and Figures:
Table 2012-2017 Global Isosorbide Key Countries Capacity List
Figure 2012-2017 Global Isosorbide Key Countries Capacity
Table 2012-2017 Global Isosorbide Key Countries Capacity Share List
Figure 2012-2017 Global Isosorbide Key Countries Capacity Share
Table 2012-2017 Global Isosorbide Key Countries Production List
Figure 2012-2017 Global Isosorbide Key Countries Production
Table 2012-2017 Global Isosorbide Key Countries Production Share List
Figure 2012-2017 Global Isosorbide Key Countries Production Share
Table 2012-2017 Global Isosorbide Key Countries Consumption Volume List
Figure 2012-2017 Global Isosorbide Key Countries Consumption Volume
Table 2012-2017 Global Isosorbide Key Countries Consumption Volume Share List
Figure 2012-2017 Global Isosorbide Key Countries Consumption Volume Share
Figure 78 2012-2017 Global Isosorbide Consumption Volume Market by Application
Table 89 2012-2017 Global Isosorbide Consumption Volume Market Share List by Application
Figure 79 2012-2017 Global Isosorbide Consumption Volume Market Share by Application
Table 90 2012-2017 Chinese Isosorbide Consumption Volume Market List by Application
Contact Info: Email: [email protected] Phone: +1-646-491-9876
0 notes
Text
Angina Pectoris Treatment Market Poised to Expand at a Robust Pace Over
Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heart’s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest.
The factors that trigger stable angina pectoris include, emotional stress, exposure to very hot or cold temperature, heavy meals or smoking. Angina pectoris can be diagnosed by an electrocardiogram and angiography and could be treated by medication, change in life style, and surgery. A minimal invasive procedure known as angioplasty is also used to treat the angina pectoris. The pain or discomfort caused by angina pectoris is relieved with rest and nitroglycerin. Nitroglycerin relaxes the coronary arteries and other blood vessels by increasing the blood flow to the heart vessels.
Request A Sample Copy: http://bit.ly/32FHrqo
New product launches and strong pipeline is expected to fuel the growth of angina pectoris treatment market
Espero announced in June 2016, that the company received approval from the U.S. Food and Drug Administration (FDA) for GoNitro (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris, due to coronary artery disease. In February 2016, AstraZeneca sold the rights of its two medicines Plendil and Imdur for US $500Mn.
China Medical System Holdings (CMS) agreed to pay AstraZeneca US $310 million for commercialization rights of Plendil (felodipine) in China. Plendil is a calcium antagonist indicated for both hypertension and the prophylaxis of the chronic stable angina pectoris. Whereas, Imdur is an oral extended-release formulation of isosorbide mononitrate indicated for the prevention of angina pectoris, due to coronary artery disease.
Furthermore, Amgen offers a product named Corlanor (Ivabradine) for the treatment of angina pectoris in its pipeline (phase 3), which was presented by the company in year 2015 at Annual Scientific Session. In November 2016, Allergan also presented new data on BYSTOLIC (nebivolol) for the treatment of hypertension to lower blood pressure at the Annual American Heart Association Meeting in New Orleans.
Whereas, Perrigo announced FDA approval of its abbreviated new drug application (ANDA) for Nitroglycerin Lingual Spray in 2013, the generic version of Shionogi's Nitrolingual Pumpspray indicated for acute attacks and prophylaxis of angina pectoris.
Strategic activities by market players to increase their market share
Angina pectoris treatment market is driven by factors, such as increasing number of collaborations, product launches, and mergers and acquisition. For instance, Recordati acquired AstraZeneca blood pressure brand Metoprolol, in 2017, which is a beta-blocker used mainly for the conditions, such as angina pectoris, hypertension, and heart disorders.
Furthermore, Pharmaceutical manufacturer Lupin received approval from U.S. FDA in 2017 to launch the generic version of the U.S WorldMeds’ nadolol drug indicated for the patients with angina pectoris and for the treatment of hypertension. Moreover, patent expiry of Ranolazine drug from Gilead Sciences, Inc. in 2019 would mark the opportunity for generic drug manufacturers in the global angina pectoris treatment market.
The key players operating in the global market of angina pectoris treatment market include Abbott Laboratories, Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Allergan plc, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and Sanofi SA.
Click To Read More On: Angina Pectoris Treatment Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Angina Pectoris Treatment Market Size, Growth and Comparison by Regions
Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heart’s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest. The factors that trigger stable angina pectoris include, emotional stress, exposure to very hot or cold temperature, heavy meals or smoking. Angina pectoris can be diagnosed by an electrocardiogram and angiography and could be treated by medication, change in life style, and surgery. A minimal invasive procedure known as angioplasty is also used to treat the angina pectoris. The pain or discomfort caused by angina pectoris is relieved with rest and nitroglycerin. Nitroglycerin relaxes the coronary arteries and other blood vessels by increasing the blood flow to the heart vessels.
Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1158
New product launches and strong pipeline is expected to fuel the growth of angina pectoris treatment market
Espero announced in June 2016, that the company received approval from the U.S. Food and Drug Administration (FDA) for GoNitro (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris, due to coronary artery disease. In February 2016, AstraZeneca sold the rights of its two medicines Plendil and Imdur for US $500Mn. China Medical System Holdings (CMS) agreed to pay AstraZeneca US $310 million for commercialization rights of Plendil (felodipine) in China. Plendil is a calcium antagonist indicated for both hypertension and the prophylaxis of the chronic stable angina pectoris. Whereas, Imdur is an oral extended-release formulation of isosorbide mononitrate indicated for the prevention of angina pectoris, due to coronary artery disease.
Furthermore, Amgen offers a product named Corlanor (Ivabradine) for the treatment of angina pectoris in its pipeline (phase 3), which was presented by the company in year 2015 at Annual Scientific Session. In November 2016, Allergan also presented new data on BYSTOLIC (nebivolol) for the treatment of hypertension to lower blood pressure at the Annual American Heart Association Meeting in New Orleans. Whereas, Perrigo announced FDA approval of its abbreviated new drug application (ANDA) for Nitroglycerin Lingual Spray in 2013, the generic version of Shionogi’s Nitrolingual Pumpspray indicated for acute attacks and prophylaxis of angina pectoris.
Strategic activities by market players to increase their market share
Angina pectoris treatment market is driven by factors, such as increasing number of collaborations, product launches, and mergers and acquisition. For instance, Recordati acquired AstraZeneca blood pressure brand Metoprolol, in 2017, which is a beta-blocker used mainly for the conditions, such as angina pectoris, hypertension, and heart disorders. Furthermore, Pharmaceutical manufacturer Lupin received approval from U.S. FDA in 2017 to launch the generic version of the U.S WorldMeds’ nadolol drug indicated for the patients with angina pectoris and for the treatment of hypertension. Moreover, patent expiry of Ranolazine drug from Gilead Sciences, Inc. in 2019 would mark the opportunity for generic drug manufacturers in the global angina pectoris treatment market.
The key players operating in the global market of angina pectoris treatment market include Abbott Laboratories, Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Allergan plc, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and Sanofi SA.
Click To Reading More On Angina Pectoris Treatment Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected]
0 notes
Text
Global Sorbitol Market Report with Latest Trends and Applications of 2018
A recent study by Transparency Market Research (TMR) forecasts that the global sorbitol market will grow at a healthy CAGR of 3.4% from 2012 to 2018. TMR, a leading market intelligence firm based in the U.S., says in its latest report that the demand for sorbitol was 1,699.7 kilo tons in 2011, and will surge to 2,148.9 kilo tons by the end of 2018. The report is titled ‘Global Sorbitol Market - Isosorbide, Propylene Glycol, Glycerol & Other Downstream Opportunities, Applications Size, Share, Growth, Trends And Forecast 2012 - 2018’
The growing awareness regarding health concerns, particularly in the context of using healthier alternatives to sugar, is a key driver boosting the sorbitol market. Sorbitol is a basic raw material required in the production of surfactants and Vitamin C. As compared to other dietary sugars, sorbitol is a metabolized slowly.
The use of sorbitol is increasing in the global market because it is being explored as a base chemical for production of propylene glycols, ethylene glycols, and glycerols – all predominantly derived from petrochemicals. The product base in the sorbitol market is almost the same as other polyols and isosorbides. Such an increasing application scope for isosorbides and polyols has resulted in a high potential for sorbitol market.
The study also analyzes various sorbitol product forms that include crystal and liquid. Liquid sorbitol is mainly manufactured based on numerous processes such as purification of dextrose, hydrogenation, and purification. Crystal sorbitol, on the other hand, is obtained after spray-drying, incurring extra cost. Liquid sorbitol accounted for 83.3% of the overall demand in 2011 and continues to dominate the global sorbitol product segments.
Similarly, toothpaste, diabetic and dietetic F and B, Vitamin C, and surfactants are some of the key applications within the global sorbitol market. Diabetic and dietetic F and B and toothpaste accounted for 23.6% and 21.3% of the overall demand in 2011, respectively.
Request to view Sample Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=847
As sorbitol is less sweet in comparison to other sugar alcohols, this market finds growing applications in various industry verticals including pharmaceutical, food & beverage, cosmetic and personal care, and the chemical industry. It is the relatively low sweetness in sorbitol that makes it a preferential choice among several diabetic patients across the globe. The rising diabetic and dietetic population is primarily boosting the market growth of sorbitol. Sorbitol allows the diabetic population to enjoy the sweetness of sugar and control their weight and other dietary illnesses. Hence, increasing sorbitol application as a low-calorie sweetener is expected to boost the global demand for sorbitol over the next five years.
Excessive sweetness creates dental problems and that is precisely why sorbitol is preferred to sugar, as it inhibits the formation of acids in the mouth that results in dental cavities. However, the global sorbitol market is restrained by variable raw material prices and side effects caused by sorbitol upon excessive consumption.
In terms of consumption, North America and Europe dominated the global sorbitol market in the earlier stages. The European sorbitol market is expected to grow at a rapid CAGR of 12.5% from 2012 to 2018. Demand for sorbitol soars in Asia-Pacific as well. The Asia Pacific sorbitol demand is mainly dominated by four regions including India, Indonesia, China, and Japan.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States
Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com
0 notes
Text
Anti-anginal Drugs Market : Review with Forecast Research Report 2017 - 2025
Anti-anginal drugs are also known as anti-anginal agents. The management of angina is done through a variety of anti-anginal drugs. Angina is a heart condition in which the arteries of the heart, known as coronary arteries, become narrow. The primary symptom associated with angina is severe chest pain. Anti-anginal agents include nitrates, calcium antagonists, beta blockers, and Ranolazine. Examples of nitrates include nitroglycerin, isosorbide mono-nitrate, and isosorbide di-nitrate. These drugs help by relaxing the smooth muscle inside the blood vessels, making it wide and helping in the easy transfer of oxygen and blood to the heart. Examples of the calcium antagonists include verapamil, nimodipine, nifedipine, and diltiazem. These antagonists inhibit the contraction of the vascular smooth muscles due to their ability to inhibit calcium transfer into the cells. Examples of beta blockers include metoprolol, pindolol, propranolol, and atenolol. These drugs help in slowing down the heartbeat.
Read Report Overview: https://www.transparencymarketresearch.com/anti-anginal-drugs-market.html
The exact way in which Ranolazine exerts its anti-anginal effect is not yet known. It is assumed that during cardiac repolarization, Ranolazine inhibits the ion channels. Anti-anginal drugs help in the treatment of Raynaud’s syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attack, esophageal spasm, cyanide poisoning, angina pectoris prophylaxis, angina, and anal fissure and fistula. Raynaud’s syndrome is an indication of blockage of blood flow to the nose, ears, toes, and fingers, causing blood vessel spasms due to experiencing of strong emotions or cold temperatures. Pulmonary hypertension occurs due to narrowing of the small arteries of the lung, making it difficult for the blood to flow, thereby increasing the blood pressure. Under this condition, the right side of the heart pumps blood harder. Hence, the size of the heart increases over a period of time, resulting in heart failure. Heart failure is a condition in which the heart is not able to transfer nutrients and oxygen to the rest of the body. Heart attack is a condition of permanent damage or death of an area of the heart muscle due to inadequate supply of oxygen to that part of the heart.
Esophageal spasms occur when the food in the esophagus does not effectively propel down to the stomach due to irregular contractions of muscles in the esophagus. The measures undertaken to prevent discomfort due to coronary heart disease or chest pain is known as angina pectoris prophylaxis. Rise in prevalence of Raynaud’s syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attack, esophageal spasms, cyanide poisoning, angina pectoris prophylaxis, angina, and anal fissure and fistula is projected to drive the anti-anginal drugs market during the forecast period. According to the Raynaud’s Association, 15 million to 30 million people in the U.S. are affected with Raynaud’s syndrome.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42011
The global anti-anginal drugs market can be segmented on the basis of mode of action, indication, dosage form, distribution channel, and region. Based on mode of action, the anti-anginal drugs market can be categorized into nitrates, calcium antagonists, beta blockers, and Ranolazine. In terms of indication, the anti-anginal drugs market can be classified into Raynaud’s syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attack, esophageal spasms, cyanide poisoning, angina pectoris prophylaxis, angina, and anal fissure and fistula. Based on dosage form, the anti-anginal drugs market can be divided into ointments and tablets. In terms of distribution channel, the anti-anginal drugs market can be bifurcated into retail pharmacies, online pharmacies, and hospital pharmacies.
Geographically, the global anti-anginal drugs market can be segmented into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America accounted for the dominant share of the anti-anginal drugs market in 2016 due to increase in prevalence of the heart failure and heart attack in the region. Europe constituted the next leading share of the anti-anginal drugs market share in 2016 owing to increase in prevalence of high blood pressure in the region. The anti-anginal drugs market in Asia Pacific is anticipated to expand at a significant rate during the forecast period. The anti-anginal drugs market in Middle East & Africa and Latin America is projected to expand during the forecast period owing to increase in initiatives undertaken by the governments to prevent incidences of heart attack and heart failure in these regions.
Request For TOC : https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=42011
Key players operating in the global anti-anginal drugs market include Pfizer Inc., MEDA Manufacturing GmbH, Valeant Pharmaceuticals International, Inc., and Gilead Sciences.
About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact us:
Transparency Market Research 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 USA – Canada Toll Free 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com/
0 notes